What are the major opportunities in the Vasomotor Menopausal Symptoms (VMS) Treatment market? What are the strategies for the Vasomotor Menopausal Symptoms (VMS) Treatment market?

For detailed insights on the major opportunities and strategies in the Vasomotor Menopausal Symptoms (VMS) Treatment market, Read More

How does the Vasomotor Menopausal Symptoms (VMS) Treatment market relate to the overall economy and other similar markets?

For detailed insights on Vasomotor Menopausal Symptoms (VMS) Treatment's relation to the overall economy and other similar markets, Read More

What are the key dynamics influencing the Vasomotor Menopausal Symptoms (VMS) Treatment market growth? SWOT analysis of the Vasomotor Menopausal Symptoms (VMS) Treatment market.

For detailed insights on the key dynamics influencing the Vasomotor Menopausal Symptoms (VMS) Treatment market growth and SWOT analysis of the Vasomotor Menopausal Symptoms (VMS) Treatment industry, Read More

Vasomotor Menopausal Symptoms (VMS) Treatment Market Global Report 2026 Market Report Infographic Image

Item added to cart!

Published : February 2026

Pages : 175

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00

Purchase This Report Download Sample PDF

Purchase This Report

Vasomotor Menopausal Symptoms (VMS) Treatment Market Report 2026

Name: Vasomotor Menopausal Symptoms (VMS) Treatment Market Report 2026
Brand: The Business Research Company
Price: 4490.00 USD
Availability: InStock

Global Outlook – By Drug Class (Antidepressants, Fluoxetine, Paroxetine, Sertraline, Hormone Therapy, Anticonvulsant, Other Drug Classes ), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels), By End-User (Hospitals, Specialty Clinics, Homecare, Other End-Users) - Market Size, Trends, And Global Forecast 2025-2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview

• Vasomotor Menopausal Symptoms (VMS) Treatment market size has reached to $19.01 billion in 2025

• Expected to grow to $26.48 billion in 2030 at a compound annual growth rate (CAGR) of 7.1%

• Growth Driver: Government Women's Health Initiatives Boost Vasomotor Menopausal Symptom Treatment Market

• Market Trend: Increasing The Emphasis On Drug Approvals To Provide Better Treatment Options

• North America was the largest region in 2025.

What Is Covered Under Vasomotor Menopausal Symptoms (VMS) Treatment Market?

Vasomotor menopausal symptoms (VMS) treatment refers to the medical interventions and therapies used to alleviate or manage the various symptoms associated with menopause. Women experience the symptoms of VMS during menopause, which include hot flashes and night sweats. The treatment works by balancing hormone levels in the body and altering neurotransmitters in the brain.

The main types of drugs in vasomotor menopausal symptoms (VMS) treatment are antidepressants, fluoxetine, paroxetine, sertraline, hormone therapy, anticonvulsants, phenytoin, phenobarbital and others. Antidepressants refer to a class of medications primarily used to treat depression and certain other mental health disorders. They are distributed in several ways, such as in hospital pharmacies, online pharmacies, retail pharmacies and others for various end-users such as hospitals, specialty clinics, homecare and others.

Vasomotor Menopausal Symptoms (VMS) Treatment Market Global Report 2026 Market Report bar graph

What Is The Vasomotor Menopausal Symptoms (VMS) Treatment Market Size and Share 2026?

The vasomotor menopausal symptoms (vms) treatment market size has grown strongly in recent years. It will grow from $19.01 billion in 2025 to $20.16 billion in 2026 at a compound annual growth rate (CAGR) of 6.0%. The growth in the historic period can be attributed to increasing prevalence of menopausal symptoms, widespread use of hormone replacement therapy, growing clinical research on neurotransmitter-based treatments, expansion of women’s health services, improved access to specialty clinics.

What Is The Vasomotor Menopausal Symptoms (VMS) Treatment Market Growth Forecast?

The vasomotor menopausal symptoms (vms) treatment market size is expected to see strong growth in the next few years. It will grow to $26.48 billion in 2030 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to rising demand for non-hormonal treatment alternatives, increasing awareness of menopause-related health management, growing investments in women’s health research, expansion of telemedicine-based treatment delivery, development of next-generation VMS therapeutics. Major trends in the forecast period include increasing development of non-hormonal therapies, growing adoption of personalized menopause treatment plans, rising use of digital health platforms for symptom management, expansion of combination drug therapies, enhanced focus on long-term safety profiles.

Book your 30 minutes free consultation with our research experts

Global Vasomotor Menopausal Symptoms (VMS) Treatment Market Segmentation

1) By Drug Class: Antidepressants, Fluoxetine, Paroxetine, Sertraline, Hormone Therapy, Anticonvulsant, Other Drug Classes

2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

3) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users

Subsegments:

1) By Antidepressants: SSRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors), TCAs (Tricyclic Antidepressants), MAOIs (Monoamine Oxidase Inhibitors), Atypical Antidepressants

2) By Fluoxetine: Depression, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Generalized Anxiety Disorder (GAD), Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Premenstrual Dysphoric Disorder (PMDD)

3) By Paroxetine: Depression, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Generalized Anxiety Disorder (GAD), Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Premenstrual Dysphoric Disorder (PMDD)

4) By Sertraline: Depression, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Premenstrual Dysphoric Disorder (PMDD)

5) By Hormone Therapy: Estrogen Replacement Therapy (ERT), Progestin Therapy, Combined Hormonal Therapy (CHT), Testosterone Replacement Therapy (TRT)

6) By Anticonvulsant: Hydantoins, Barbiturates, Benzodiazepines, Valproates, Succinimides, Carboxylic Acid Derivatives

7) By Other Drug Classes: Antibiotics, Analgesics, Antidiabetics, Antihypertensives, Anticoagulants, Immunosuppressants, Antipsychotics, Antihistamines

What Is The Driver Of The Vasomotor Menopausal Symptoms (VMS) Treatment Market?

The government's initiatives for women's health in menopause are expected to propel the growth of the vasomotor menopausal symptom’s treatment market going forward. Government initiatives for menopausal health encompass funding for innovative studies on menopausal transition, illness prevention, and research related pharmacological, clinical, and epidemiological aspects. These efforts are part of broader women's health initiatives that address diverse concerns. For instance, in January 2023, according to the Government of New South Wales, an Australia-based government agency, the government initiated $40.3 million over four years (2022-2023 to 2025-2026) to build up to 16 new programs for women facing severe menopausal symptoms. Therefore, the government's initiatives for women's health in menopause are driving the growth of the vasomotor menopausal symptoms’ treatment market.

Key Players In The Global Vasomotor Menopausal Symptoms (VMS) Treatment Market

Major companies operating in the vasomotor menopausal symptoms (vms) treatment market are Pfizer Inc., Abbvie Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Kyowa Kirin Co. Ltd., Dr. Reddy's Laboratories Ltd., Alembic Pharmaceuticals Limited Inc., Apotex Inc., Hikma Pharmaceutical plc, Endo Pharmaceuticals plc, Amneal Pharmaceuticals LLC, Mundipharma International Ltd., Lupin Limited, Glenmark Pharmaceuticals Ltd., Hisamitsu Pharmaceutical Co. Inc., Emcure Pharmaceuticals Limited, Wockhardt Pvt. Ltd., QuatRx Pharmaceuticals Company, Bionovo Inc., Mithra Pharmaceuticals SA, EndoCeutics Inc., Zydus Group, Edgemont Pharmaceuticals LLC, MenoGeniX Inc., Agile Therapeutics Inc

Global Vasomotor Menopausal Symptoms (VMS) Treatment Market Trends and Insights

Major companies operating in the vasomotor menopausal symptoms treatment market are developing products such as Veozah and getting approvals to provide new treatment options and meet unmet medical needs for patients. The approval of new drugs for menopause provides improved efficacy and safety compared to existing treatments. For instance, in May 2023, Astellas Pharma Inc, a Japan-based pharmaceutical company, received approval for Veozah (fezolinetant) 45 mg once daily from the Food and Drug Administration (FDA), a US-based federal agency for the treatment of menopausal vasomotor symptoms (VMS), which range from mild to severe. It is the first nonhormonal neurokinin 3 (NK3) receptor antagonist to be authorized for treating menopausal-related VMS. It is a hormone-free option that blocks a pathway in the brain that helps regulate these symptoms. It provides an alternative treatment option for women experiencing these symptoms, particularly those who cannot or prefer not to use hormone therapy. The approval of Veozah highlights its potential as a new drug for managing menopausal symptoms.

Need data on a specific region in this market?

Request Regional Data

What Are Latest Mergers And Acquisitions In The Vasomotor Menopausal Symptoms (VMS) Treatment Market?

In November 2023, Pharmavite LLC, a US-based nutrition and wellness company, acquired Bonafide Health for US $425 million. Through this acquisition, Pharmavite aimed to strengthen its women’s health offerings by integrating Bonafide’s clinically supported, hormone-free menopause products, including options to relieve vasomotor symptoms such as hot flashes and night sweats, as well as products for vaginal dryness and other menopause-related concerns. Bonafide Health LLC is a US-based women’s health brand specializing in science-backed, over-the-counter (non-prescription) products designed to address symptoms associated with estrogen decline.

Regional Outlook

North America was the largest region in the vasomotor menopausal symptoms (VMS) treatment market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Vasomotor Menopausal Symptoms (VMS) Treatment Market?

The vasomotor menopausal symptoms (VMS) treatment market consists of revenues earned by entities by providing services such as cognitive-behavioral therapy, acupuncture, lifestyle modifications, herbal and vitamin supplements and complementary and alternative therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The vasomotor menopausal symptoms (VMS) treatment market also includes sales of natural supplements, cooling products, vaginal estrogen products, stress-reduction products, sleep aids and dietary supplements. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Vasomotor Menopausal Symptoms (VMS) Treatment Market Report 2026?

The vasomotor menopausal symptoms (vms) treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the vasomotor menopausal symptoms (vms) treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Author : Abdul Wasay

Vasomotor Menopausal Symptoms (VMS) Treatment Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2026	$20.16 billion
Revenue Forecast In 2035	$26.48 billion
Growth Rate	CAGR of 6.0% from 2026 to 2035
Base Year For Estimation	2025
Actual Estimates/Historical Data	2020-2025
Forecast Period	2026 - 2030 - 2035
Market Representation	Revenue in USD Billion and CAGR from 2026 to 2035
Segments Covered	Drug Class, Distribution Channel, End-User
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, ...
Key Companies Profiled	Pfizer Inc., Abbvie Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Kyowa Kirin Co. Ltd., Dr. Reddy's Laboratories Ltd., Alembic Pharmaceuticals Limited Inc., Apotex Inc., Hikma Pharmaceutical plc, Endo Pharmaceuticals plc, Amneal Pharmaceuticals LLC, Mundipharma International Ltd., Lupin Limited, Glenmark Pharmaceuticals Ltd., Hisamitsu Pharmaceutical Co. Inc., Emcure Pharmaceuticals Limited, Wockhardt Pvt. Ltd., QuatRx Pharmaceuticals Company, Bionovo Inc., Mithra Pharmaceuticals SA, EndoCeutics Inc., Zydus Group, Edgemont Pharmaceuticals LLC, MenoGeniX Inc., Agile Therapeutics Inc
Customization Scope	Request for Customization
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

1.1. Key Market Insights (2020-2035)

1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots

1.3. Major Factors Driving the Market

1.4. Top Three Trends Shaping the Market

2. Vasomotor Menopausal Symptoms (VMS) Treatment Market Characteristics

2.1. Market Definition & Scope

2.2. Market Segmentations

2.3. Overview of Key Products and Services

2.4. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market Attractiveness Scoring And Analysis

2.4.1. Overview of Market Attractiveness Framework

2.4.2. Quantitative Scoring Methodology

2.4.3. Factor-Wise Evaluation

Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation

2.4.5. Strategic Implications and Recommendations

3. Vasomotor Menopausal Symptoms (VMS) Treatment Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem

3.2. List Of Key Raw Materials, Resources & Suppliers

3.3. List Of Major Distributors and Channel Partners

3.4. List Of Major End Users

4. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market Trends And Strategies

4.1. Key Technologies & Future Trends

4.1.1 Biotechnology, Genomics & Precision Medicine

4.1.2 Digitalization, Cloud, Big Data & Cybersecurity

4.1.3 Artificial Intelligence & Autonomous Intelligence

4.1.4 Sustainability, Climate Tech & Circular Economy

4.1.5 Industry 4.0 & Intelligent Manufacturing

4.2. Major Trends

4.2.1 Increasing Development Of Non-Hormonal Therapies

4.2.2 Growing Adoption Of Personalized Menopause Treatment Plans

4.2.3 Rising Use Of Digital Health Platforms For Symptom Management

4.2.4 Expansion Of Combination Drug Therapies

4.2.5 Enhanced Focus On Long-Term Safety Profiles

5. Vasomotor Menopausal Symptoms (VMS) Treatment Market Analysis Of End Use Industries

5.1 Hospitals

5.2 Specialty Clinics

5.3 Homecare Providers

5.4 Women’S Health Centers

5.5 Ambulatory Care Centers

6. Vasomotor Menopausal Symptoms (VMS) Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Vasomotor Menopausal Symptoms (VMS) Treatment Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global Vasomotor Menopausal Symptoms (VMS) Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

7.2. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market Size, Comparisons And Growth Rate Analysis

7.3. Global Vasomotor Menopausal Symptoms (VMS) Treatment Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)

7.4. Global Vasomotor Menopausal Symptoms (VMS) Treatment Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Vasomotor Menopausal Symptoms (VMS) Treatment Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)

8.2. Methodology and Assumptions

8.3. Global Total Addressable Market (TAM) Estimation

8.4. TAM vs. Current Market Size Analysis

8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Vasomotor Menopausal Symptoms (VMS) Treatment Market Segmentation

9.1. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Antidepressants, Fluoxetine, Paroxetine, Sertraline, Hormone Therapy, Anticonvulsant, Other Drug Classes

9.2. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

9.3. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Hospitals, Specialty Clinics, Homecare, Other End-Users

9.4. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Antidepressants, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

SSRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors), TCAs (Tricyclic Antidepressants), MAOIs (Monoamine Oxide Inhibitors), Atypical Antidepressants

9.5. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Fluoxetine, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Depression, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Generalized Anxiety Disorder (GAD), Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Premenstrual Dysphoric Disorder (PMDD)

9.6. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Paroxetine, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

9.7. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Sertraline, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Depression, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Premenstrual Dysphoric Disorder (PMDD)

9.8. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Hormone Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Estrogen Replacement Therapy (ERT), Progestin Therapy, Combined Hormonal Therapy (CHT), Testosterone Replacement Therapy (TRT)

9.9. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Anticonvulsant, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Hydantoins, Barbiturates, Benzodiazepines, Valproates, Succinimides, Carboxylic Acid Derivatives

9.10. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Antibiotics, Analgesics, Antidiabetics, Antihypertensives, Anticoagulants, Immunosuppressants, Antipsychotics, Antihistamines

10. Vasomotor Menopausal Symptoms (VMS) Treatment Market Regional And Country Analysis

10.1. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

10.2. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Vasomotor Menopausal Symptoms (VMS) Treatment Market

11.1. Asia-Pacific Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

11.2. Asia-Pacific Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Vasomotor Menopausal Symptoms (VMS) Treatment Market

12.1. China Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

12.2. China Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Vasomotor Menopausal Symptoms (VMS) Treatment Market

13.1. India Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market

14.1. Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview

14.2. Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Vasomotor Menopausal Symptoms (VMS) Treatment Market

15.1. Australia Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Vasomotor Menopausal Symptoms (VMS) Treatment Market

16.1. Indonesia Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Vasomotor Menopausal Symptoms (VMS) Treatment Market

17.1. South Korea Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview

17.2. South Korea Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Vasomotor Menopausal Symptoms (VMS) Treatment Market

18.1. Taiwan Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview

18.2. Taiwan Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Vasomotor Menopausal Symptoms (VMS) Treatment Market

19.1. South East Asia Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview

19.2. South East Asia Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market

20.1. Western Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview

20.2. Western Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Vasomotor Menopausal Symptoms (VMS) Treatment Market

21.1. UK Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Vasomotor Menopausal Symptoms (VMS) Treatment Market

22.1. Germany Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Vasomotor Menopausal Symptoms (VMS) Treatment Market

23.1. France Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Vasomotor Menopausal Symptoms (VMS) Treatment Market

24.1. Italy Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Vasomotor Menopausal Symptoms (VMS) Treatment Market

25.1. Spain Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market

26.1. Eastern Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview

26.2. Eastern Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Vasomotor Menopausal Symptoms (VMS) Treatment Market

27.1. Russia Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Vasomotor Menopausal Symptoms (VMS) Treatment Market

28.1. North America Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview

28.2. North America Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Vasomotor Menopausal Symptoms (VMS) Treatment Market

29.1. USA Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview

29.2. USA Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Vasomotor Menopausal Symptoms (VMS) Treatment Market

30.1. Canada Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview

30.2. Canada Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Vasomotor Menopausal Symptoms (VMS) Treatment Market

31.1. South America Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview

31.2. South America Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Vasomotor Menopausal Symptoms (VMS) Treatment Market

32.1. Brazil Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Vasomotor Menopausal Symptoms (VMS) Treatment Market

33.1. Middle East Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview

33.2. Middle East Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Vasomotor Menopausal Symptoms (VMS) Treatment Market

34.1. Africa Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview

34.2. Africa Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Vasomotor Menopausal Symptoms (VMS) Treatment Market Regulatory and Investment Landscape

36. Vasomotor Menopausal Symptoms (VMS) Treatment Market Competitive Landscape And Company Profiles

36.1. Vasomotor Menopausal Symptoms (VMS) Treatment Market Competitive Landscape And Market Share 2024

36.1.1. Top 10 Companies (Ranked by revenue/share)

36.2. Vasomotor Menopausal Symptoms (VMS) Treatment Market - Company Scoring Matrix

36.2.1. Market Revenues

36.2.2. Product Innovation Score

36.2.3. Brand Recognition

36.3. Vasomotor Menopausal Symptoms (VMS) Treatment Market Company Profiles

36.3.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

36.3.2. Abbvie Inc. Overview, Products and Services, Strategy and Financial Analysis

36.3.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

36.3.4. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis

36.3.5. Mylan N.V. Overview, Products and Services, Strategy and Financial Analysis

37. Vasomotor Menopausal Symptoms (VMS) Treatment Market Other Major And Innovative Companies

Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Kyowa Kirin Co. Ltd., Dr. Reddy's Laboratories Ltd., Alembic Pharmaceuticals Limited Inc., Apotex Inc., Hikma Pharmaceutical plc, Endo Pharmaceuticals plc, Amneal Pharmaceuticals LLC, Mundipharma International Ltd., Lupin Limited, Glenmark Pharmaceuticals Ltd., Hisamitsu Pharmaceutical Co. Inc., Emcure Pharmaceuticals Limited, Wockhardt Pvt. Ltd.

38. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Vasomotor Menopausal Symptoms (VMS) Treatment Market

40. Vasomotor Menopausal Symptoms (VMS) Treatment Market High Potential Countries, Segments and Strategies

40.1 Vasomotor Menopausal Symptoms (VMS) Treatment Market In 2030 - Countries Offering Most New Opportunities

40.2 Vasomotor Menopausal Symptoms (VMS) Treatment Market In 2030 - Segments Offering Most New Opportunities

40.3 Vasomotor Menopausal Symptoms (VMS) Treatment Market In 2030 - Growth Strategies

40.3.1 Market Trend Based Strategies

40.3.2 Competitor Strategies

41. Appendix

41.1. Abbreviations

41.2. Currencies

41.3. Historic And Forecast Inflation Rates

41.4. Research Inquiries

41.5. The Business Research Company

41.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Overview Of Key Products - Product Examples

Table 2: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market Attractiveness, Factor-Wise Evaluation

Table 3: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Supply Chain Analysis

Table 4: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Major Raw Material Providers

Table 5: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Major Resource Providers

Table 6: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Major Manufacturers (Suppliers)

Table 7: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Major Distributors And Channel Partners

Table 8: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Key Technologies & Future Trends

Table 9: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Major Trends

Table 10: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Major End Users

Table 11: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis

Table 12: Global Vasomotor Menopausal Symptoms (VMS) Treatment Historic Market Growth, 2020-2025, $ Billion

Table 13: Global Vasomotor Menopausal Symptoms (VMS) Treatment Forecast Market Growth, 2025-2030F, 2035F, $ Billion

Table 14: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market - TAM, US$ Billion, 2025

Table 15: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 16: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 17: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 18: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Antidepressants, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 19: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Fluoxetine, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 20: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Paroxetine, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 21: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Sertraline, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 22: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Hormone Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 23: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Anticonvulsant, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 24: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 25: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 26: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 27: Asia-Pacific, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 28: Asia-Pacific, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 29: Asia-Pacific, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 30: China, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 31: China, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 32: China, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 33: India, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 34: India, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 35: India, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 36: Japan, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 37: Japan, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 38: Japan, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 39: Australia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 40: Australia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 41: Australia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 42: Indonesia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 43: Indonesia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 44: Indonesia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 45: South Korea, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 46: South Korea, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 47: South Korea, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 48: Taiwan, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 49: Taiwan, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 50: Taiwan, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 51: South East Asia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 52: South East Asia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 53: South East Asia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 54: Western Europe, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 55: Western Europe, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 56: Western Europe, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 57: UK, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 58: UK, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 59: UK, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 60: Germany, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 61: Germany, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 62: Germany, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 63: France, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 64: France, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 65: France, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 66: Italy, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 67: Italy, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 68: Italy, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 69: Spain, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 70: Spain, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 71: Spain, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 72: Eastern Europe, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 73: Eastern Europe, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 74: Eastern Europe, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 75: Russia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 76: Russia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 77: Russia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 78: North America, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 79: North America, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 80: North America, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 81: USA, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 82: USA, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 83: USA, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 84: Canada, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 85: Canada, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 86: Canada, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 87: South America, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 88: South America, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 89: South America, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 90: Brazil, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 91: Brazil, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 92: Brazil, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 93: Middle East, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 94: Middle East, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 95: Middle East, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 96: Africa, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 97: Africa, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 98: Africa, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 99: Global Vasomotor Menopausal Symptoms (VMS) Treatment Key Competitor Estimated Market Shares, 2024, Percentage (%)

Table 100: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market - Company Scoring Matrix

Table 101: Pfizer Inc. Financial Performance

Table 102: Abbvie Inc. Financial Performance

Table 103: Novartis AG Financial Performance

Table 104: Teva Pharmaceutical Industries Ltd. Financial Performance

Table 105: Mylan N.V. Financial Performance

Table 106: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Competitive Benchmarking (In USD Billions)

Table 107: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Competitive Dashboard

Table 108: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market Size Gain ($ Billion), 2025 – 2030 By Country

Table 109: Global, Vasomotor Menopausal Symptoms (VMS) Treatment Market Size Gain ($ Billion), Segmentation By Drug Class, 2025 – 2030

Table 110: Global, Vasomotor Menopausal Symptoms (VMS) Treatment Market Size Gain ($ Billion), Segmentation By Distribution Channel, 2025 – 2030

Table 111: Global, Vasomotor Menopausal Symptoms (VMS) Treatment Market Size Gain ($ Billion), Segmentation By End-User, 2025 – 2030

List Of Figures

Figure 1: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Overview Of Key Products - Product Examples

Figure 2: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market Attractiveness, Factor-Wise Evaluation

Figure 3: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Supply Chain Analysis

Figure 4: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Major Raw Material Providers

Figure 5: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Major Resource Providers

Figure 6: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Major Manufacturers (Suppliers)

Figure 7: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Major Distributors And Channel Partners

Figure 8: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Key Technologies & Future Trends

Figure 9: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Major Trends

Figure 10: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Major End Users

Figure 11: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis

Figure 12: Global Vasomotor Menopausal Symptoms (VMS) Treatment Historic Market Growth, 2020-2025, $ Billion

Figure 13: Global Vasomotor Menopausal Symptoms (VMS) Treatment Forecast Market Growth, 2025-2030F, 2035F, $ Billion

Figure 14: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market - TAM, US$ Billion, 2025

Figure 15: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 16: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 17: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 18: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Antidepressants, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 19: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Fluoxetine, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 20: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Paroxetine, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 21: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Sertraline, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 22: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Hormone Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 23: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Anticonvulsant, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 24: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 25: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 26: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 27: Asia-Pacific, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 28: Asia-Pacific, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 29: Asia-Pacific, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 30: China, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 31: China, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 32: China, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 33: India, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 34: India, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 35: India, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 36: Japan, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 37: Japan, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 38: Japan, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 39: Australia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 40: Australia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 41: Australia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 42: Indonesia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 43: Indonesia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 44: Indonesia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 45: South Korea, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 46: South Korea, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 47: South Korea, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 48: Taiwan, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 49: Taiwan, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 50: Taiwan, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 51: South East Asia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 52: South East Asia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 53: South East Asia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 54: Western Europe, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 55: Western Europe, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 56: Western Europe, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 57: UK, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 58: UK, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 59: UK, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 60: Germany, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 61: Germany, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 62: Germany, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 63: France, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 64: France, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 65: France, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 66: Italy, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 67: Italy, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 68: Italy, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 69: Spain, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 70: Spain, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 71: Spain, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 72: Eastern Europe, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 73: Eastern Europe, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 74: Eastern Europe, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 75: Russia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 76: Russia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 77: Russia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 78: North America, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 79: North America, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 80: North America, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 81: USA, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 82: USA, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 83: USA, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 84: Canada, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 85: Canada, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 86: Canada, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 87: South America, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 88: South America, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 89: South America, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 90: Brazil, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 91: Brazil, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 92: Brazil, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 93: Middle East, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 94: Middle East, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 95: Middle East, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 96: Africa, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 97: Africa, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 98: Africa, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 99: Global Vasomotor Menopausal Symptoms (VMS) Treatment Key Competitor Estimated Market Shares, 2024, Percentage (%)

Figure 100: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market - Company Scoring Matrix

Figure 101: Pfizer Inc. Financial Performance

Figure 102: Abbvie Inc. Financial Performance

Figure 103: Novartis AG Financial Performance

Figure 104: Teva Pharmaceutical Industries Ltd. Financial Performance

Figure 105: Mylan N.V. Financial Performance

Figure 106: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Competitive Benchmarking (In USD Billions)

Figure 107: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Competitive Dashboard

Figure 108: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market Size Gain ($ Billion), 2025 – 2030 By Country

Figure 109: Global, Vasomotor Menopausal Symptoms (VMS) Treatment Market Size Gain ($ Billion), Segmentation By Drug Class, 2025 – 2030

Figure 110: Global, Vasomotor Menopausal Symptoms (VMS) Treatment Market Size Gain ($ Billion), Segmentation By Distribution Channel, 2025 – 2030

Figure 111: Global, Vasomotor Menopausal Symptoms (VMS) Treatment Market Size Gain ($ Billion), Segmentation By End-User, 2025 – 2030

Global Acute Care Telemedicine Market Forecast to Reach $66.59 Billion by 2029, Driven by 17.7% CAGR

Strategic Report on Gender Reassignment Surgery Market: Growth Opportunities and Emerging Challenges

In-Depth Health Check-Up Market Report: Business Trends, Growth Factors, and Forecast to 2029

Global Insights: Healthcare Digital Experience Platform Market Expected to Surpass $4.34 Billion by 2029

A strategic 2025 report providing key insights, trends and forecasts for the global live attenuated polio vaccine market between 2025–2034.

A 2025 forecast report outlining growth projections, key trends and regulatory landscape of the medicated shampoo market through 2029.

Explore strategic insights and forecasts in the global virtual nutrition coach app market, offering competitive benchmarking and market growth trends.

Explore the latest trends, growth insights, and forecasts in the Key Trend Shaping The Ophthalmology Medical Service Market.

Menopausal Hot Flashes Market Report 2026 - Global Outlook – By Type (Hormonal Treatment, Non-Hormonal Treatment, Alternative Treatment), By Pipeline Analysis (Phase III Drugs, Phase I And II Drugs), By Distribution Chan...

Menopause Market Report 2026 - Global Outlook – By Treatment (Dietary Supplements, Over-The-Counter (OTC) Pharma Products), By Route Of Administration (Topical, Oral, Injectables), By Distribution Channel (Hospital, Reta...

Vulvodynia Treatment Market Report 2026 - Global Outlook – By Drug Type (Anticonvulsants, Tricyclic Antidepressants, Local Anesthetics, Antimicrobials, Hormone Creams, Nerve Blocks, Other Drug Types), By Route Of Adminis...

Vaginitis Therapeutics Market Report 2026 - Global Outlook – By Drug Type (Nitroimidazole Compound, Lincosamide Antibiotics, Triazoles, Imidazoles), By Route Of Administration (Oral, Cutaneous, Vaginal), By Indication Ty...

Vaginal Rejuvenation Market Report 2026 - Global Outlook – By Type (Surgical, Non-Surgical), By Treatment Type (Reconstructive Vaginal Rejuvenation, Cosmetic Vaginal Rejuvenation), By Application (Incontinence, Aesthetic...

Vitiligo Treatment Market Report 2026 - Global Outlook – By Drugs (Antihistamines, H2 Antagonists, Tricyclic Antidepressants, Other Drugs), By Types (Acute Urticaria, Chronic Urticaria), By Mode Of Administration (Inject...

Virology Testing Market Report 2026 - Global Outlook – By Type (Instruments, Assay Kits And Consumables), By Diagnostic Technique (Molecular Diagnostics Method, Immunoassay Based Method, Mass Spectroscopy Based Method, O...

Frequently Asked Questions

How big is the Vasomotor Menopausal Symptoms (VMS) Treatment Market?

The Vasomotor Menopausal Symptoms (VMS) Treatment market was valued at $19.01 billion in 2025, increased to $20.16 billion in 2026, and is projected to reach $26.48 billion by 2030.

What is the Vasomotor Menopausal Symptoms (VMS) Treatment market growth?

The global Vasomotor Menopausal Symptoms (VMS) Treatment market is expected to grow at a CAGR of 7.1% from 2026 to 2035 to reach $26.48 billion by 2035.

Who are the key players in Vasomotor Menopausal Symptoms (VMS) Treatment market?

Some Key Players in the Vasomotor Menopausal Symptoms (VMS) Treatment market Include, Pfizer Inc., Abbvie Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Kyowa Kirin Co. Ltd., Dr. Reddy's Laboratories Ltd., Alembic Pharmaceuticals Limited Inc., Apotex Inc., Hikma Pharmaceutical plc, Endo Pharmaceuticals plc, Amneal Pharmaceuticals LLC, Mundipharma International Ltd., Lupin Limited, Glenmark Pharmaceuticals Ltd., Hisamitsu Pharmaceutical Co. Inc., Emcure Pharmaceuticals Limited, Wockhardt Pvt. Ltd., QuatRx Pharmaceuticals Company, Bionovo Inc., Mithra Pharmaceuticals SA, EndoCeutics Inc., Zydus Group, Edgemont Pharmaceuticals LLC, MenoGeniX Inc., Agile Therapeutics Inc .

What is the anticipated growth trend for the Vasomotor Menopausal Symptoms (VMS) Treatment market?

Major trend in this market includes: Increasing The Emphasis On Drug Approvals To Provide Better Treatment Options. For further insights on this market. request a sample here

Which region has the most growth potential in the Vasomotor Menopausal Symptoms (VMS) Treatment market?

North America was the largest region in the vasomotor menopausal symptoms (VMS) treatment market in 2025. The regions covered in the vasomotor menopausal symptoms (vms) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.